A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)
Condition: Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ
MeSH terms: Uterine Cervical Dysplasia; Adenocarcinoma in Situ
Intervention: V501
Intervention description: 0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6
Intervention MeSH terms: Vaccines
Phase: Phase 3
Study type: Interventional
Primary purpose: Prevention
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 766.0
Sex: Female
Minimum age: 9 Years
Maximum age: 26 Years
Healthy volunteers: Accepts Healthy Volunteers

Summary:

      This study is designed to evaluate the immunogenicity, safety, and tolerability of Gardasil®
      (quadrivalent human papillomavirus [qHPV] vaccine, V501) in Chinese girls aged 9-19 years and
      young women aged 20-26 years. The primary hypothesis of the study states that at 1 month
      postdose 3, a 3-dose regimen of V501 induces non-inferior geometric mean titers (GMTs) for
      serum anti-HPV 6, anti-HPV 11, anti-HPV 16, anti-HPV 18 in girls aged 9-19 years compared to
      young women aged 20-26 years.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Not pregnant and 1) not a woman of childbearing potential (WOCBP), or 2) a WOCBP who
             has not had sex with males or has had sex with males and used effective contraception
             since the first day of participant's last menstrual period through Day 1 and
             understands and agrees that during the study she should not have sexual intercourse
             with males without effective contraception (the rhythm method, withdrawal, and
             emergency contraception are not acceptable methods per the protocol).

          -  Participant and participant's parent or guardian (participants aged 9-17 years only)
             provided written informed consent/assent.

          -  Provided a primary and alternative telephone for follow-up purposes.

          -  Extension Stage: participant was enrolled in the 9-19 years old group, received 3
             doses of V501 in the Base Stage, and participant and participant's legally acceptable
             representative (if applicable) provided written informed consent/assent for the study
             extension.

        Exclusion Criteria:

          -  History of severe allergic reaction that required medical intervention.

          -  Allergic to any vaccine component, including aluminum, yeast, or Benzonase®
             (nuclease).

          -  Known thrombocytopenia or any coagulation disorder that would contraindicate
             intramuscular injections.

          -  Currently immunocompromised or was diagnosed as having congenital or acquired
             immunodeficiency, human immunodeficiency virus (HIV) infection, lymphoma, leukemia,
             systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid
             arthritis (JRA), inflammatory bowel disease, or other autoimmune condition.

          -  History of splenectomy.

          -  Any condition which in the opinion of the investigator might interfere with the
             evaluation of the study objectives.

          -  History of recent or ongoing alcohol or other drug abuse.

          -  History of a positive test for HPV.

          -  Any history of abnormal Pap test.

          -  History of external genital wart, vulvar intraepithelial neoplasia (VIN), vaginal
             intraepithelial neoplasia (VaIN), vulvar cancer or vaginal cancer.

          -  Undergone hysterectomy (either vaginal or total abdominal hysterectomy).

          -  Receiving or has received in the year prior to Day 1 vaccination an excluded
             immunosuppressive therapy. A participant will be excluded if she is currently
             receiving steroid therapy, has recently received such therapy, or has received 2 or
             more courses of corticosteroids (orally or parenterally) lasting at least 1 week in
             duration in the year prior to Day 1 vaccination. Participants using inhaled, nasal or
             topical steroids are considered eligible for the study.

          -  Received immune globulin product or blood-derived product within 6 months prior to Day
             1 vaccination, or plans to receive any such product during the study.

          -  Received a marketed HPV vaccine, or has participated in an HPV vaccine clinical trial
             and has received either active agent or placebo.

          -  Received inactivated or recombinant vaccines within 14 days prior to Day 1 vaccination
             or receipt of live vaccines within 21 days prior to Day 1 vaccination.

          -  Concurrently enrolled in a clinical study of investigational agents.

          -  Had >4 lifetime sexual partners.

          -  Unlikely to adhere to the study procedures, keep appointments, or is planning to
             permanently relocate from the area prior to the completion of the study or to leave
             for an extended period of time when study visits would need to be scheduled.

          -  An immediate family member who is investigational site or sponsor staff directly
             involved with this study.

          -  Extension Stage: reported overdose or received non-study HPV vaccine during the Base
             Stage.